AYOLLARDA BACHADON BO‘YNI KASALLIKLARINI ERTA TASHXISLASH VA PROFILAKTIKA QILISH USULLARI
Keywords:
bachadon bo‘yni, HPV, sitologiya, skrining, kolposkopiya, displaziya, emlash, profilaktika.Abstract
Ushbu tezisda bachadon bo‘ynining yallig‘lanish kasalliklari, inson papilloma virusi (HPV) bilan bog‘liq o‘zgarishlar, prekanseroz holatlar va bachadon bo‘yni saratonini erta aniqlashning zamonaviy yondashuvlari tahlil qilinadi. HPV DNK testi, sitologiya, kolposkopiya va gistologik tekshiruvning klinik vazifalari qiyoslanadi. Birlamchi va ikkilamchi profilaktika, xavf guruhlarini ajratish, skrining natijalaridan keyingi kuzatuv hamda ayollarning tibbiy xizmatdan foydalanish imkoniyati muhokama etiladi. Tezis xalqaro qo‘llanmalar va epidemiologik ilmiy adabiyotlar sharhiga asoslangan bo‘lib, klinik tajribada olingan yangi statistik natijalarni da’vo qilmaydi.
References
1.World Health Organization. (2026). Cervical cancer [Fact sheet]. https://www.who.int/news-room/fact-sheets/detail/cervical-cancer
2.International Agency for Research on Cancer. (2022). Cervical cancer screening (IARC Handbooks of Cancer Prevention, Vol. 18). IARC. https://publications.iarc.who.int/604
3.World Health Organization. (2021). WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention (2nd ed.). https://www.who.int/publications/i/item/9789240030824
4.Arbyn, M., Weiderpass, E., Bruni, L., de Sanjosé, S., Saraiya, M., Ferlay, J., & Bray, F. (2020). Estimates of incidence and mortality of cervical cancer in 2018: A worldwide analysis. The Lancet Global Health, 8(2), e191–e203. https://doi.org/10.1016/S2214-109X(19)30482-6
5.World Health Organization. (2024). WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention: Use of dual-stain cytology to triage women after a positive test for HPV. https://www.who.int/publications/i/item/9789240091658
6.Perkins, R. B., Guido, R. S., Castle, P. E., et al. (2020). 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. Journal of Lower Genital Tract Disease, 24(2), 102–131. https://doi.org/10.1097/LGT.0000000000000525
7.Fontham, E. T. H., Wolf, A. M. D., Church, T. R., et al. (2020). Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA: A Cancer Journal for Clinicians, 70(5), 321–346. https://doi.org/10.3322/caac.21628
8.World Health Organization. (2020). Global strategy to accelerate the elimination of cervical cancer as a public health problem. https://www.who.int/publications/i/item/9789240014107
9.Curry, S. J., Krist, A. H., Owens, D. K., et al. (2018). Screening for cervical cancer: US Preventive Services Task Force recommendation statement. JAMA, 320(7), 674–686. https://doi.org/10.1001/jama.2018.10897
10.World Health Organization. (2026). WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention: Use of HPV DNA genotyping. https://www.who.int/publications/b/82716
